News

HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36

HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $34 to $36.

Benzinga·02:13NRIX▲+5.4%

Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways

SeekingAlpha·02:46NRIX▲+5.4%

RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $35

RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and lowers the price target from $36 to $35.

Benzinga·06:54NRIX▲+5.4%

Oppenheimer Maintains Outperform on Nurix Therapeutics, Raises Price Target to $32

Oppenheimer analyst Kostas Biliouris maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $28 to $32.

Benzinga·05:26NRIX▲+5.4%

Truist Securities Maintains Buy on Nurix Therapeutics, Lowers Price Target to $33

Truist Securities analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and lowers the price target from $34 to $33.

Benzinga·04:48NRIX▲+5.4%

Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36

Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.

Benzinga·03:48NRIX▲+5.4%

Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target

Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $34 price target.

Benzinga·02:24NRIX▲+5.4%

Nurix Therapeutics falls 2% following Q3 earnings as operating expenses up

Investing.com -- Nurix Therapeutics Inc (NASDAQ:NRIX) reported third quarter fiscal 2026 financial results on Monday, with revenue of $673.1 million, up significantly from $7.9 million in the same quarter last year. The company posted adjusted earnings per share of $4.73, compared to a loss of -$1.03 per share in the prior-year period. Shares are down 2% in after hours trading following the earnings release, though they were up nearly 8% shortly after.

Yahoo·16:59NRIX▲+5.4%

Stock Market: Will S&P 500 Open Up or Down Today?

Will S&P 500 open higher? Polymarket odds sit at 52% as Wall Street weighs 5.35% Treasury yields, potential Iran strikes, and Pepsi earnings.

Benzinga·22:12

Is Extending the Gilead E3 Ligase Collaboration Altering The Investment Case For Nurix Therapeutics (NRIX)?

Nurix Therapeutics, Inc. recently announced that it has extended by two years the research term for an undisclosed oncology program under its ongoing collaboration with Gilead Sciences, originally established in 2019 to develop E3 ligase–based protein degradation therapies. This extension underscores continued progress in a partnership that could earn Nurix up to approximately US$1.30 billion in potential payments, plus tiered royalties on any future commercial products, with options for...

Yahoo·19:17NRIX▲+5.4%

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia

First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation of bexobrutideg given in combination with venetoclax and selected antibodies in the Roche portfolio of B-cell malignancy therapies BRISBANE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced that the first patient has been enrolled in the Phase 1b/2 NX-594

Yahoo·01:00NRIX▲+5.4%

Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche Collaboration

First patient enrolled in cohort combining bexobrutideg with venetoclaxInitial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLLStrategy includes evaluation of bexobrutideg given in

Benzinga·21:36NRIX▲+5.4%